Atrium Therapeutics, Inc. Common Stock - Asset Resilience Ratio
Atrium Therapeutics, Inc. Common Stock (RNA) has an Asset Resilience Ratio of 68.61% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See RNA working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2024)
This chart shows how Atrium Therapeutics, Inc. Common Stock's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see RNA total assets.
Liquid Assets Composition Over Time
This chart breaks down Atrium Therapeutics, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read RNA total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $939.24 Million | 68.61% |
| Total Liquid Assets | $939.24 Million | 68.61% |
Asset Resilience Insights
- Very High Liquidity: Atrium Therapeutics, Inc. Common Stock maintains exceptional liquid asset reserves at 68.61% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Atrium Therapeutics, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Atrium Therapeutics, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 16.06% |
|
Genscript Biotech Corporation
F:G51 |
Biotechnology | 13.79% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
89bio Inc
NASDAQ:ETNB |
Biotechnology | 71.60% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 2.66% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
Annual Asset Resilience Ratio for Atrium Therapeutics, Inc. Common Stock (2020–2024)
The table below shows the annual Asset Resilience Ratio data for Atrium Therapeutics, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 81.95% | $1.28 Billion | $1.56 Billion | +16.68pp |
| 2023-12-31 | 65.27% | $410.27 Million | $628.55 Million | +22.95pp |
| 2022-12-31 | 42.32% | $270.33 Million | $638.80 Million | +22.42pp |
| 2021-12-31 | 19.90% | $85.09 Million | $427.58 Million | +17.90pp |
| 2020-12-31 | 2.00% | $6.68 Million | $333.90 Million | -- |
About Atrium Therapeutics, Inc. Common Stock
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treat… Read more